Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) was the recipient of unusually large options trading activity on Thursday. Investors bought 42,588 put options on the stock. This represents an increase of 240% compared to the average volume of 12,513 put options.
Gilead Sciences Trading Down 2.3 %
Shares of NASDAQ:GILD traded down $1.53 during trading on Thursday, reaching $65.55. The stock had a trading volume of 4,851,889 shares, compared to its average volume of 7,281,077. The business has a fifty day moving average price of $71.56 and a 200-day moving average price of $76.39. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The stock has a market cap of $81.61 billion, a P/E ratio of 14.98, a PEG ratio of 0.96 and a beta of 0.19. Gilead Sciences has a fifty-two week low of $65.32 and a fifty-two week high of $87.86.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. During the same period last year, the company posted $1.67 EPS. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. As a group, analysts anticipate that Gilead Sciences will post 5.24 earnings per share for the current fiscal year.
Gilead Sciences Increases Dividend
Analyst Ratings Changes
Several analysts have recently weighed in on GILD shares. Truist Financial downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and lowered their target price for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a report on Wednesday. StockNews.com downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, April 19th. Cantor Fitzgerald decreased their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. Finally, Royal Bank of Canada decreased their price objective on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 14th. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $84.57.
Check Out Our Latest Stock Report on GILD
Insider Buying and Selling
In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is owned by company insiders.
Hedge Funds Weigh In On Gilead Sciences
Several institutional investors and hedge funds have recently bought and sold shares of GILD. Altfest L J & Co. Inc. purchased a new stake in Gilead Sciences during the fourth quarter worth approximately $210,000. Federated Hermes Inc. grew its stake in Gilead Sciences by 4.9% during the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock worth $306,814,000 after buying an additional 175,925 shares during the period. Wetzel Investment Advisors Inc. purchased a new stake in Gilead Sciences during the fourth quarter worth approximately $74,000. Abundance Wealth Counselors purchased a new stake in Gilead Sciences during the third quarter worth approximately $1,881,000. Finally, HTLF Bank purchased a new stake in Gilead Sciences during the fourth quarter worth approximately $253,000. Institutional investors and hedge funds own 83.67% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
- Five stocks we like better than Gilead Sciences
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Hasbro’s Management Made All the Right Calls This Quarter
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Why Invest in High-Yield Dividend Stocks?
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.